Successful outcome of invasive aspergillosis (IA) depends upon:
With the availability of tools for early diagnosis (e.g., high-resolution computed tomography scan, fungal biomarkers), the outlook has considerably improved. In addition, antifungal drugs such as voriconazole are more effective and better tolerated than amphotericin B.[2]Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Aug 15;63(4):e1-e60.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967602
http://www.ncbi.nlm.nih.gov/pubmed/27365388?tool=bestpractice.com
Establishing early diagnosis and initiating treatment are also key to improving prognosis of chronic pulmonary aspergillosis (CPA).[127]Lowes D, Al-Shair K, Newton PJ, et al. Predictors of mortality in chronic pulmonary aspergillosis. Eur Respir J. 2017 Feb 8;49(2):1601062.
https://erj.ersjournals.com/content/49/2/1601062.long
http://www.ncbi.nlm.nih.gov/pubmed/28179437?tool=bestpractice.com
Risk of death
The following factors have been reported to increase the risk of death from IA:
After haematopoietic stem cell transplantation: graft-versus-host disease; neutropenia; cytomegalovirus seropositivity; prolonged use of corticosteroids; prolonged immunosuppression; disseminated IA; presence of pleural effusion and monocyte count <120 cells/mm³
After heart, lung, liver, and kidney transplantation: hyperimmunosuppression; renal failure; stormy postoperative course; recurrent bacterial infection; old age.[1]Barnes PD, Marr KA. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin North Am. 2006 Sep;20(3):545-61,
http://www.ncbi.nlm.nih.gov/pubmed/16984868?tool=bestpractice.com
In one cohort study of patients with CPA, survival at 1, 5, and 10 years was 86%, 62%, and 47%, respectively.[127]Lowes D, Al-Shair K, Newton PJ, et al. Predictors of mortality in chronic pulmonary aspergillosis. Eur Respir J. 2017 Feb 8;49(2):1601062.
https://erj.ersjournals.com/content/49/2/1601062.long
http://www.ncbi.nlm.nih.gov/pubmed/28179437?tool=bestpractice.com
The following factors were reported to increase the risk of death:
Non-tuberculous mycobacterial infection, COPD, pleural involvement, cavitary disease, presence of an aspergilloma, shortness of breath, low physical activity, and low body mass.
In patients with aspergilloma, untreated severe haemoptysis is frequently fatal.
Recurrence
After successful treatment of invasive aspergillosis, Aspergillus remains quiescent/dormant until immunosuppression is restarted. In patients with a prior history of invasive aspergillosis, the infection may relapse when immunosuppressive therapy is reintroduced or increased. In such cases, secondary prophylaxis with antifungal therapy may be reasonable.[2]Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Aug 15;63(4):e1-e60.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967602
http://www.ncbi.nlm.nih.gov/pubmed/27365388?tool=bestpractice.com
[128]Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis. 2006 Jun 1;42(11):1584-91.
https://academic.oup.com/cid/article/42/11/1584/282801
http://www.ncbi.nlm.nih.gov/pubmed/16652316?tool=bestpractice.com
Relapse of CPA is relatively common after antifungal therapy is stopped, and long-term treatment may be necessary.[3]Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016 Jan;47(1):45-68.
https://erj.ersjournals.com/content/47/1/45.long
http://www.ncbi.nlm.nih.gov/pubmed/26699723?tool=bestpractice.com
[4]Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015 Mar;70(3):270-7.
https://thorax.bmj.com/content/70/3/270.long
http://www.ncbi.nlm.nih.gov/pubmed/25354514?tool=bestpractice.com
[129]Bongomin F, Otu A, Harris C, et al. Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy. Clin Infect Pract. 2020 Apr;5:100015.
https://www.sciencedirect.com/science/article/pii/S2590170220300029